Emergent BioSolutions Q3 2024 revenue $293.8M (+9% YoY), net income $114.8M, raises FY2024 guidance

Emergent BioSolutions Inc.

2024-Q3 EPS reported -$3.03 revenue$848,900,000

Q3 2024 total revenues $293.8M, up 9% year-over-year; net income $114.8M vs loss of $263.4M in Q3 2023.
Adjusted EBITDA surged 432% to $105.3M; company raises FY2024 revenue guidance to $1.065B-$1.125B.
Entered new $250M term loan with OHA Agency and $100M asset-backed loan with Wells Fargo.
Completed asset sales: RSDL product to SERB for $75M, Baltimore-Camden site for $35M, Canton warehouse for $7M.
Received $50M from Janssen contractual dispute resolution and $30M milestone from Bavarian Nordic.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.